Metformin protects against hyperglycemia-induced cardiomyocytes injury by inhibiting the expressions of receptor for advanced glycation end products and high mobility group box 1 protein
Authors:
- 14 January 2014
- journal article
- research article
- Published by Springer Nature in Molecular Biology Reports
- Vol. 41 (3) , 1335-1340
Abstract
Metformin (MET), an anti-diabetic oral drug with antioxidant properties, has been proved to provide cardioprotective effects in patients with diabetic disease. However, the mechanism is unclear. This study aimd to investigate the effects of MET on the expressions of receptor for advanced glycation end products (RAGE) and high mobility group box 1 protein (HMGB1) in hyperglycemia-treated neonatal rat ventricular myocytes. Cardiocytes were prepared and cultured with high glucose and different concentrations of MET. The expressions of RAGE and HMGB1 were evaluated by Western blot analysis. The superoxide dismutase (SOD), malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), lactate dehydrogenase (LDH) and creatine kinase (CK) were measured. After 12 h-incubation, MET significantly inhibited the increase of MDA, TNF-α, LDH and CK levels induced by high glucose, especially at the 5 × 10−5 to 10−4 mol/L concentrations while inhibiting the decrease of SOD level. Meanwhile, RAGE and HMGB1 expression were significantly increased induced by hyperglycaemia for 24 h (P < 0.05). MET inhibited the expressions of RAGE and HMGB1 in a dose-dependent manner, especially at the 5 × 10−5 to 10−4 mol/L concentrations (P < 0.05). In conclusion, our study suggested that MET could reduce hyperglycemia-induced cardiocytes injury by inhibiting the expressions of RAGE and HMGB1.Keywords
This publication has 32 references indexed in Scilit:
- Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expressionChemico-Biological Interactions, 2011
- The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitusActa Diabetologica, 2011
- Increased serum high mobility group box 1 protein in patients with atrial fibrillationBiomedicine & Aging Pathology, 2011
- Metformin improves cardiac function in rats via activation of AMP‐activated protein kinaseClinical and Experimental Pharmacology and Physiology, 2010
- Metformin inhibits HMGB1 release in LPS‐treated RAW 264.7 cells and increases survival rate of endotoxaemic miceBritish Journal of Pharmacology, 2010
- Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathwayBiochemical and Biophysical Research Communications, 2010
- Metformin: A Therapeutic Opportunity in Breast CancerClinical Cancer Research, 2010
- Hyperglycemia-Induced Reactive Oxygen Species Increase Expression of the Receptor for Advanced Glycation End Products (RAGE) and RAGE LigandsDiabetes, 2009
- Metformin Attenuated the Autoimmune Disease of the Central Nervous System in Animal Models of Multiple SclerosisThe Journal of Immunology, 2009
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998